tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

INCY Stock Latest News

Knight Therapeutics announces approval, launch of MINJUVI in Argentina
The FlyKnight Therapeutics announces approval, launch of MINJUVI in Argentina
3d ago
INCY
Incyte price target raised to $93 from $79 at Truist
PremiumThe Fly
Incyte price target raised to $93 from $79 at Truist
4d ago
INCY
Incyte price target raised to $84 from $81 at RBC Capital
PremiumThe Fly
Incyte price target raised to $84 from $81 at RBC Capital
4d ago
INCY
Incyte price target raised to $109 from $104 at BofA
PremiumThe Fly
Incyte price target raised to $109 from $104 at BofA
4d ago
INCY
Incyte’s Strong Financial Performance and Strategic Catalysts Drive Buy Rating
PremiumRatings
Incyte’s Strong Financial Performance and Strategic Catalysts Drive Buy Rating
4d ago
INCY
Incyte price target raised to $97 from $89 at Wells Fargo
PremiumThe FlyIncyte price target raised to $97 from $89 at Wells Fargo
4d ago
INCY
Incyte price target raised to $101 from $90 at Barclays
Premium
The Fly
Incyte price target raised to $101 from $90 at Barclays
4d ago
INCY
Incyte Reports Strong Q3 2025 Financial Results
Premium
Company Announcements
Incyte Reports Strong Q3 2025 Financial Results
5d ago
INCY
Incyte’s Earnings Call: Strong Growth and Optimism
PremiumCompany Announcements
Incyte’s Earnings Call: Strong Growth and Optimism
5d ago
INCY
Incyte’s Strong Performance Overshadowed by Pipeline Uncertainties: Analyst Recommends Hold
PremiumRatings
Incyte’s Strong Performance Overshadowed by Pipeline Uncertainties: Analyst Recommends Hold
5d ago
INCY
Incyte sees FY25 net product revenue $4.23B-$4.32B
PremiumThe Fly
Incyte sees FY25 net product revenue $4.23B-$4.32B
5d ago
INCY
Incyte reports Q3 EPS $2.26, consensus $1.64
PremiumThe Fly
Incyte reports Q3 EPS $2.26, consensus $1.64
5d ago
INCY
Incyte’s Ruxolitinib Cream Study: A Potential Game-Changer for Hidradenitis Suppurativa
PremiumCompany AnnouncementsIncyte’s Ruxolitinib Cream Study: A Potential Game-Changer for Hidradenitis Suppurativa
6d ago
INCY
Incyte’s Ruxolitinib Cream Study: A Potential Breakthrough for Pediatric Vitiligo
Premium
Company Announcements
Incyte’s Ruxolitinib Cream Study: A Potential Breakthrough for Pediatric Vitiligo
6d ago
INCY
Incyte’s Latest Clinical Study: A Step Forward in Drug Development
Premium
Company Announcements
Incyte’s Latest Clinical Study: A Step Forward in Drug Development
6d ago
INCY
Incyte’s Phase 3 Study on Povorcitinib: A Potential Game-Changer for Prurigo Nodularis
PremiumCompany Announcements
Incyte’s Phase 3 Study on Povorcitinib: A Potential Game-Changer for Prurigo Nodularis
6d ago
INCY
Incyte’s Promising Phase 3 Study on Axatilimab for cGVHD: What Investors Should Know
PremiumCompany Announcements
Incyte’s Promising Phase 3 Study on Axatilimab for cGVHD: What Investors Should Know
6d ago
INCY
Incyte’s Axatilimab Study: A Potential Game-Changer for cGVHD Treatment
PremiumCompany Announcements
Incyte’s Axatilimab Study: A Potential Game-Changer for cGVHD Treatment
6d ago
INCY
Incyte’s Promising Study on Ruxolitinib Cream for Pediatric Atopic Dermatitis
PremiumCompany Announcements
Incyte’s Promising Study on Ruxolitinib Cream for Pediatric Atopic Dermatitis
6d ago
INCY
Incyte’s Phase 3 Study on Ruxolitinib Cream for Hidradenitis Suppurativa: A Market Game-Changer?
PremiumCompany AnnouncementsIncyte’s Phase 3 Study on Ruxolitinib Cream for Hidradenitis Suppurativa: A Market Game-Changer?
6d ago
INCY
Incyte’s New Study on INCA035784: A Potential Breakthrough in Myeloproliferative Neoplasms
Premium
Company Announcements
Incyte’s New Study on INCA035784: A Potential Breakthrough in Myeloproliferative Neoplasms
6d ago
INCY
Incyte’s Phase 2 Study on INCB123667: A Potential Breakthrough in Ovarian Cancer Treatment
Premium
Company Announcements
Incyte’s Phase 2 Study on INCB123667: A Potential Breakthrough in Ovarian Cancer Treatment
6d ago
INCY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >